Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 2,726 - 2,750 of 2,778

«
1
…
108
109
110
111
112
»

Telemedicine in Oncology

Telemedicine in Oncology

By: Jack West, MD

Telemedicine in Oncology

Telemedicine in Oncology

By: Jack West, MD

Artificial Intelligence in Oncology Care

Artificial Intelligence in Oncology Care

By: Kristina Rua, MSN, RN, OCN, ONN-CG

Artificial Intelligence in Oncology Care

Artificial Intelligence in Oncology Care

By: Kristina Rua, MSN, RN, OCN, ONN-CG

Artificial Intelligence-Aided Lung Biopsy: Proof-of-Concept in Percutaneous Needle Pathway Selection

Artificial Intelligence-Aided Lung Biopsy: Proof-of-Concept in Percutaneous Needle Pathway Selection

By: Meridith Kisting, MA

Telemedicine in Oncology

Telemedicine in Oncology

By: Nate Gross, MD

Telemedicine in Oncology

Telemedicine in Oncology

By: Nate Gross, MD

Testicular Cancer: The Old, The New, The Future

Testicular Cancer: The Old, The New, The Future

By: Pasquale W. Benedetto, MD

Testicular Cancer: The Old, The New, The Future

Testicular Cancer: The Old, The New, The Future

By: Pasquale W. Benedetto, MD

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

By: Christine M. Lovly, MD, PhD

Strategies to Target Minimal Residual Disease

Strategies to Target Minimal Residual Disease

By: Christine M. Lovly, MD, PhD

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

By: Fred Hirsch, MD

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

MRD to Decide Perioperative Management in the Era of Immuno-Oncology

By: Fred Hirsch, MD

Immunotherapy Related Adverse Reactions

Immunotherapy Related Adverse Reactions

By: Helen Shih, NP, MPH

Immune-Related Adverse Events (irAE) Checkpoint Inhibitors

Immune-Related Adverse Events (irAE) Checkpoint Inhibitors

By: Helen Shih, NP, MPH

ALK-Altered Non-Squamous NSCLC Options and Sequence

ALK-Altered Non-Squamous NSCLC Options and Sequence

By: Jacob Sands, MD

Neoadjuvant Treatment in Thoracic Surgery

Neoadjuvant Treatment in Thoracic Surgery

By: Jae Kim, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

By: Jorge E. Gomez, MD

Systemic Therapies for Mesothelioma

Systemic Therapies for Mesothelioma

By: Jorge E. Gomez, MD

ALK Mutant NSCLC

ALK Mutant NSCLC

By: Lyudmila Bazhenova, MD

Oncogene-Driven NSCLC

Oncogene-Driven NSCLC

By: Matthew Gubens MD

What Lies Beyond EGFR, ALK And ROS1 Targeted Therapies?

What Lies Beyond EGFR, ALK And ROS1 Targeted Therapies?

By: Melissa L Johnson, MD

Squamous Cell Carcinoma Standard and Novel Targets

Squamous Cell Carcinoma Standard and Novel Targets

By: Mohamed K Mohamed, MD, PhD

Squamous Cell Carcinoma Standard and Novel Targets.

Squamous Cell Carcinoma Standard and Novel Targets.

By: Mohamed K. Mohamed, MD, PhD

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going?

By: Natasha Leighl, MD

«
1
…
108
109
110
111
112
»

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok